TRACON Pharmaceuticals (TCON) announced it has collected the previously announced arbitration award from I-Mab Biopharma (IMAB).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TCON:
- Tracon announces results of six-month IDMC review of ENVASARC Phase 2 trial
- TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference
- Tracon announces enforcement action to collect arbitration award from I-Mab
- TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
- TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
